Showing results (1511-1520 of 2,107) with videos related to
Sort By:
Pageof 211
CNS Drugs|August 5, 2025
Dual Antiplatelet Therapy Versus Alteplase for Mild Stroke with Admission NIHSS Score 0-3 Versus 4-5: A Secondary Analysis of the ARAMIS Randomized TrialZhao-Xia Fei, Yue Yin, Yu Cui, et al.CNS Drugs|November 12, 2025
The Potential Clinical Use of Opioid-Receptor-Modulating Drugs in Bipolar DisorderMaria Gefke, Christina B Wagner, Roger S McIntyre, et al.CNS Drugs|July 10, 2025
Psychedelics for Alcohol Use Disorder: A Narrative Review with Candidate Mechanisms of ActionEric A Miller, Christy Capone, Erica Eaton, et al.CNS Drugs|July 8, 2025
Safety, Tolerability, and Pharmacokinetics of NRL-1049, a Rho-Associated Kinase Inhibitor, in Healthy Volunteers: A Phase 1, First-in-Human, Single-Ascending Dose, Randomized, Placebo-Controlled TrialStuart Madden, Issam Awad, Miguel A Lopez-Toledano, et al.CNS Drugs|July 10, 2025
Investigational Gene Therapies for Parkinson's DiseaseNicolas Phielipp, Claire HenchcliffeCNS Drugs|July 2, 2025
Management of Bipolar Disorder in Pregnancy and Postpartum: A Clinicians' GuideVeerle Bergink, Mariella Suleiman, Mary-Anne Hennen, et al.CNS Drugs|September 12, 2025
Incretin Hormones GLP-1 and GIP Normalize Energy Utilization and Reduce Inflammation in the Brain in Alzheimer's Disease and Parkinson's Disease: From Repurposed GLP-1 Receptor Agonists to Novel Dual GLP-1/GIP Receptor Agonists as Potential Disease-Modifying TherapiesChristian HölscherCNS Drugs|June 15, 2025
Efficacy and Safety of Once-Monthly Paliperidone Palmitate Long-Acting Injections in Chinese Patients with Early-, Mid-, and Late-Phase Schizophrenia: A Post-Hoc Analysis of Three Phase 4 StudiesQian Li, Yang Li, Yishen Yang, et al.Pageof 211